Emerging Strategies for Treating Brain Metastases from Breast Cancer

Cancer Cell

Volumn 27, Issue 2, 2015, Pages 163-175

  Kodack, David P ^a   Askoxylakis, Vasileios ^a   Ferraro, Gino B ^a   Fukumura, Dai ^a   Jain, Rakesh K ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABEMACICLIB; BEVACIZUMAB; BUPARLISIB; CABAZITAXEL; CABOZANTINIB; CAPECITABINE; CARBOPLATIN; CISPLATIN; CPG OLIGODEOXYNUCLEOTIDE; EPOTHILONE B; ETOPOSIDE; EVEROLIMUS; INIPARIB; IRBINITINIB; IRINOTECAN; LAPATINIB; NAVELBINE; NERATINIB; PACLITAXEL; PAZOPANIB; SARACATINIB; SHORT HAIRPIN RNA; SORAFENIB; TEMOZOLOMIDE; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; TREBANANIB; UNINDEXED DRUG; VARDENAFIL; VORINOSTAT; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

BLOOD BRAIN BARRIER; BRAIN METASTASIS; BREAST CANCER; CANCER RADIOTHERAPY; CANCER SURVIVAL; CAPILLARY ENDOTHELIAL CELL; DRUG EFFICACY; HUMAN; NEURAL STEM CELL; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; REVIEW; TUMOR MICROENVIRONMENT; WHOLE BODY RADIATION; BRAIN NEOPLASMS; BREAST NEOPLASMS; FEMALE; GENETICS; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; PATHOLOGY; SECONDARY;

BRAIN NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; MOLECULAR TARGETED THERAPY; PATHOLOGY, MOLECULAR; RECEPTOR, ERBB-2;

EID: 84922782200     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2015.01.001     Document Type: Review

References (98)

1. Adkins C.E., Mittapalli R.K., Manda V.K., Nounou M.I., Mohammad A.S., Terrell T.B., Bohn K.A., Yasemin C., Grothe T.R., Lockman J.A., Lockman P.R. P-glycoprotein mediated efflux limits substrate and drug uptake in a preclinical brain metastases of breast cancer model. Front. Pharmacol. 2013, 4:136.
2. Armulik A., Genové G., Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev. Cell 2011, 21:193-215.
3. Aversa C., Rossi V., Geuna E., Martinello R., Milani A., Redana S., Valabrega G., Aglietta M., Montemurro F. Metastatic breast cancer subtypes and central nervous system metastases. Breast 2014, 23:623-628.
4. Avraham H.K., Jiang S., Fu Y., Nakshatri H., Ovadia H., Avraham S. Angiopoietin-2 mediates blood-brain barrier impairment and colonization of triple-negative breast cancer cells in brain. J.Pathol. 2014, 232:369-381.
5. Bachelot T., Romieu G., Campone M., Diéras V., Cropet C., Dalenc F., Jimenez M., Le Rhun E., Pierga J.Y., Gonçalves A., et al. Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): a single-group phase 2 study. Lancet Oncol. 2013, 14:64-71.
6. Bartsch R., Rottenfusser A., Wenzel C., Dieckmann K., Pluschnig U., Altorjai G., Rudas M., Mader R.M., Poetter R., Zielinski C.C., Steger G.G. Trastuzumab prolongs overall survival in patients with brain metastases from Her2 positive breast cancer. J.Neurooncol. 2007, 85:311-317.
7. Bartsch R., Berghoff A.S., Preusser M. Breast cancer brain metastases responding to primary systemic therapy with T-DM1. J.Neurooncol. 2014, 116:205-206.
8. Baschnagel A., Russo A., Burgan W.E., Carter D., Beam K., Palmieri D., Steeg P.S., Tofilon P., Camphausen K. Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown invitro and as intracranial xenografts. Mol. Cancer Ther. 2009, 8:1589-1595.
9. Bell R.D., Winkler E.A., Sagare A.P., Singh I., LaRue B., Deane R., Zlokovic B.V. Pericytes control key neurovascular functions and neuronal phenotype in the adult brain and during brain aging. Neuron 2010, 68:409-427.
10. Bendell J.C., Domchek S.M., Burstein H.J., Harris L., Younger J., Kuter I., Bunnell C., Rue M., Gelman R., Winer E. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003, 97:2972-2977.
11. Bos P.D., Zhang X.H., Nadal C., Shu W., Gomis R.R., Nguyen D.X., Minn A.J., van de Vijver M.J., Gerald W.L., Foekens J.A., Massague J. Genes that mediate breast cancer metastasis to the brain. Nature 2009, 459:1005-1009.
12. Brown W.R., Thore C.R., Moody D.M., Robbins M.E., Wheeler K.T. Vascular damage after fractionated whole-brain irradiation in rats. Radiat. Res. 2005, 164:662-668.
13. Brufsky A.M., Hurvitz S., Perez E., Swamy R., Valero V., O'Neill V., Rugo H.S. RIBBON-2: a randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J.Clin. Oncol. 2011, 29:4286-4293.
14. Brufsky A.M., Mayer M., Rugo H.S., Kaufman P.A., Tan-Chiu E., Tripathy D., Tudor I.C., Wang L.I., Brammer M.G., Shing M., et al. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER. Clin. Cancer Res. 2011, 17:4834-4843.
15. Cameron D., Casey M., Press M., Lindquist D., Pienkowski T., Romieu C.G., Chan S., Jagiello-Gruszfeld A., Kaufman B., Crown J., et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res. Treat. 2008, 112:533-543.
16. Chen J., Lee H.J., Wu X., Huo L., Kim S.J., Xu L., Wang Y., He J., Bollu L.R., Gao G., et al. Gain of glucose-independent growth upon metastasis of breast cancer cells to the brain. Cancer Res. 2014, 75:1-12.
17. Cheng L., Huang Z., Zhou W., Wu Q., Donnola S., Liu J.K., Fang X., Sloan A.E., Mao Y., Lathia J.D., et al. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 2013, 153:139-152.
18. Chiu W.T., Lee H.T., Huang F.J., Aldape K.D., Yao J., Steeg P.S., Chou C.Y., Lu Z., Xie K., Huang S. Caveolin-1 upregulation mediates suppression of primary breast tumor growth and brain metastases by stat3 inhibition. Cancer Res. 2011, 71:4932-4943.
19. Crown J., Kennedy M.J., Tresca P., Marty M., Espie M., Burris H.A., DeSilvio M., Lau M.R., Kothari D., Koch K.M., Diéras V. Optimally tolerated dose of lapatinib in combination with docetaxel plus trastuzumab in first-line treatment of HER2-positive metastatic breast cancer. Ann. Oncol. 2013, 24:2005-2011.
20. Da Silva L., Simpson P.T., Smart C.E., Cocciardi S., Waddell N., Lane A., Morrison B.J., Vargas A.C., Healey S., Beesley J., et al. HER3 and downstream pathways are involved in colonization of brain metastases from breast cancer. Breast Cancer Res. 2010, 12:R46.
21. Deeken J.F., Löscher W. The blood-brain barrier and cancer: transporters, treatment, and Trojan horses. Clin. Cancer Res. 2007, 13:1663-1674.
22. di Tomaso E., Snuderl M., Kamoun W.S., Duda D.G., Auluck P.K., Fazlollahi L., Andronesi O.C., Frosch M.P., Wen P.Y., Plotkin S.R., et al. Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Res. 2011, 71:19-28.
23. Dietrich J., Monje M., Wefel J., Meyers C. Clinical patterns and biological correlates of cognitive dysfunction associated with cancer therapy. Oncologist 2008, 13:1285-1295.
24. Duda D.G., Duyverman A.M., Kohno M., Snuderl M., Steller E.J., Fukumura D., Jain R.K. Malignant cells facilitate lung metastasis by bringing their own soil. Proc. Natl. Acad. Sci. USA 2010, 107:21677-21682.
25. Eichler A.F., Chung E., Kodack D.P., Loeffler J.S., Fukumura D., Jain R.K. The biology of brain metastases-translation to new therapies. Nat. Rev. Clin. Oncol. 2011, 8:344-356.
26. Falchook G.S., Moulder S.L., Wheler J.J., Jiang Y., Bastida C.C., Kurzrock R. Dual HER2 inhibition in combination with anti-VEGF treatment is active in heavily pretreated HER2-positive breast cancer. Ann. Oncol. 2013, 24:3004-3011.
27. Fitzgerald D.P., Palmieri D., Hua E., Hargrave E., Herring J.M., Qian Y., Vega-Valle E., Weil R.J., Stark A.M., Vortmeyer A.O., Steeg P.S. Reactive glia are recruited by highly proliferative brain metastases of breast cancer and promote tumor cell colonization. Clin. Exp. Metastasis 2008, 25:799-810.
28. Fitzgerald D.P., Subramanian P., Deshpande M., Graves C., Gordon I., Qian Y., Snitkovsky Y., Liewehr D.J., Steinberg S.M., Paltán-Ortiz J.D., et al. Opposing effects of pigment epithelium-derived factor on breast cancer cell versus neuronal survival: implication for brain metastasis and metastasis-induced brain damage. Cancer Res. 2012, 72:144-153.
29. Gerstner E.R., Fine R.L. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J.Clin. Oncol. 2007, 25:2306-2312.
30. Ghajar C.M., Peinado H., Mori H., Matei I.R., Evason K.J., Brazier H., Almeida D., Koller A., Hajjar K.A., Stainier D.Y., et al. The perivascular niche regulates breast tumour dormancy. Nat. Cell Biol. 2013, 15:807-817.
31. Gianni L., Romieu G.H., Lichinitser M., Serrano S.V., Mansutti M., Pivot X., Mariani P., Andre F., Chan A., Lipatov O., et al. AVEREL: a randomized phase III Trial evaluating bevacizumab in combination with docetaxel and trastuzumab as first-line therapy for HER2-positive locally recurrent/metastatic breast cancer. J.Clin. Oncol. 2013, 31:1719-1725.
32. Gori S., Rimondini S., De Angelis V., Colozza M., Bisagni G., Moretti G., Sidoni A., Basurto C., Aristei C., Anastasi P., Crinò L. Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: incidence, survival, and risk factors. Oncologist 2007, 12:766-773.
33. Gril B., Palmieri D., Bronder J.L., Herring J.M., Vega-Valle E., Feigenbaum L., Liewehr D.J., Steinberg S.M., Merino M.J., Rubin S.D., Steeg P.S. Effect of lapatinib on the outgrowth of metastatic breast cancer cells to the brain. J.Natl. Cancer Inst. 2008, 100:1092-1103.
34. Gril B., Palmieri D., Qian Y., Smart D., Ileva L., Liewehr D.J., Steinberg S.M., Steeg P.S. Pazopanib reveals a role for tumor cell B-Raf in the prevention of HER2+ breast cancer brain metastasis. Clin. Cancer Res. 2011, 17:142-153.
35. Grossi P.M., Ochiai H., Archer G.E., McLendon R.E., Zalutsky M.R., Friedman A.H., Friedman H.S., Bigner D.D., Sampson J.H. Efficacy of intracerebral microinfusion of trastuzumab in an athymic rat model of intracerebral metastatic breast cancer. Clin. Cancer Res. 2003, 9:5514-5520.
36. Hu J., Ljubimova J.Y., Inoue S., Konda B., Patil R., Ding H., Espinoza A., Wawrowsky K.A., Patil C., Ljubimov A.V., Black K.L. Phosphodiesterase type 5 inhibitors increase Herceptin transport and treatment efficacy in mouse metastatic brain tumor models. PLoS ONE 2010, 5:e10108.
37. Huang F., Alrefae M., Langleben A., Roberge D. Prophylactic cranial irradiation in advanced breast cancer: a case for caution. Int. J. Radiat. Oncol. Biol. Phys. 2009, 73:752-758.
38. Izumi Y., Xu L., di Tomaso E., Fukumura D., Jain R.K. Tumour biology: Herceptin acts as an anti-angiogenic cocktail. Nature 2002, 416:279-280.
39. Jain R.K. Antiangiogenesis strategies revisited: from starving tumors to alleviating hypoxia. Cancer Cell 2014, 26:605-622.
40. Kalm M., Abel E., Wasling P., Nyman J., Hietala M.A., Bremell D., Hagberg L., Elam M., Blennow K., Björk-Eriksson T., Zetterberg H. Neurochemical evidence of potential neurotoxicity after prophylactic cranial irradiation. Int. J. Radiat. Oncol. Biol. Phys. 2014, 89:607-614.
41. Kennecke H., Yerushalmi R., Woods R., Cheang M.C., Voduc D., Speers C.H., Nielsen T.O., Gelmon K. Metastatic behavior of breast cancer subtypes. J.Clin. Oncol. 2010, 28:3271-3277.
42. Kienast Y., von Baumgarten L., Fuhrmann M., Klinkert W.E., Goldbrunner R., Herms J., Winkler F. Real-time imaging reveals the single steps of brain metastasis formation. Nat. Med. 2010, 16:116-122.
43. Kim L.S., Huang S., Lu W., Lev D.C., Price J.E. Vascular endothelial growth factor expression promotes the growth of breast cancer brain metastases in nude mice. Clin. Exp. Metastasis 2004, 21:107-118.
44. Kim S.J., Kim J.S., Park E.S., Lee J.S., Lin Q., Langley R.R., Maya M., He J., Kim S.W., Weihua Z., et al. Astrocytes upregulate survival genes in tumor cells and induce protection from chemotherapy. Neoplasia 2011, 13:286-298.
45. Kim S.W., Choi H.J., Lee H.J., He J., Wu Q., Langley R.R., Fidler I.J., Kim S.J. Role of the endothelin axis in astrocyte- and endothelial cell-mediated chemoprotection of cancer cells. Neuro. Oncol. 2014, 16:1585-1598.
46. Kocher M., Soffietti R., Abacioglu U., Villà S., Fauchon F., Baumert B.G., Fariselli L., Tzuk-Shina T., Kortmann R.D., Carrie C., et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. J.Clin. Oncol. 2011, 29:134-141.
47. Kodack D.P., Chung E., Yamashita H., Incio J., Duyverman A.M., Song Y., Farrar C.T., Huang Y., Ager E., Kamoun W., et al. Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastases. Proc. Natl. Acad. Sci. USA 2012, 109:E3119-E3127.
48. Krop I.E., Kim S.B., González-Martín A., LoRusso P.M., Ferrero J.M., Smitt M., Yu R., Leung A.C., Wildiers H. Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial. Lancet Oncol. 2014, 15:689-699. TH3RESA Study Collaborators.
49. Lampson L.A. Monoclonal antibodies in neuro-oncology: getting past the blood-brain barrier. MAbs 2011, 3:153-160.
50. Le Péchoux C., Laplanche A., Faivre-Finn C., Ciuleanu T., Wanders R., Lerouge D., Keus R., Hatton M., Videtic G.M., Senan S., et al. Clinical neurological outcome and quality of life among patients with limited small-cell cancer treated with two different doses of prophylactic cranial irradiation in the intergroup phase III trial (PCI99-01, EORTC 22003-08004, RTOG 0212 and IFCT 99-01). Ann. Oncol. 2011, 22:1154-1163.
51. Lee S.J., Seol H.J., Lee H.W., Kang W.Y., Kang B.G., Jin J., Jo M.Y., Jin Y., Lee J.I., Joo K.M., Nam D.H. Gene silencing of c-Met leads to brain metastasis inhibitory effects. Clin. Exp. Metastasis 2013, 30:845-854.
52. Lin N.U., Carey L.A., Liu M.C., Younger J., Come S.E., Ewend M., Harris G.J., Bullitt E., Van den Abbeele A.D., Henson J.W., et al. Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J.Clin. Oncol. 2008, 26:1993-1999.
53. Lin N.U., Diéras V., Paul D., Lossignol D., Christodoulou C., Stemmler H.J., Roché H., Liu M.C., Greil R., Ciruelos E., et al. Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin. Cancer Res. 2009, 15:1452-1459.
54. Liu H., Kato Y., Erzinger S.A., Kiriakova G.M., Qian Y., Palmieri D., Steeg P.S., Price J.E. The role of MMP-1 in breast cancer growth and metastasis to the brain in a xenograft model. BMC Cancer 2012, 12:583.
55. Lombardi G., Di Stefano A.L., Farina P., Zagonel V., Tabouret E. Systemic treatments for brain metastases from breast cancer, non-small cell lung cancer, melanoma and renal cell carcinoma: an overview of the literature. Cancer Treat. Rev. 2014, 40:951-959.
56. Lorger M., Felding-Habermann B. Capturing changes in the brain microenvironment during initial steps of breast cancer brain metastasis. Am. J. Pathol. 2010, 176:2958-2971.
57. Lorger M., Krueger J.S., O'Neal M., Staflin K., Felding-Habermann B. Activation of tumor cell integrin alphavbeta3 controls angiogenesis and metastatic growth in the brain. Proc. Natl. Acad. Sci. USA 2009, 106:10666-10671.
58. Louie E., Chen X.F., Coomes A., Ji K., Tsirka S., Chen E.I. Neurotrophin-3 modulates breast cancer cells and the microenvironment to promote the growth of breast cancer brain metastasis. Oncogene 2013, 32:4064-4077.
59. Malin D., Strekalova E., Petrovic V., Deal A.M., Al Ahmad A., Adamo B., Miller C.R., Ugolkov A., Livasy C., Fritchie K., et al. AlphaB-crystallin: a novel regulator of breast cancer metastasis to the brain. Clin. Cancer Res. 2014, 20:56-67.
60. Margolin K., Ernstoff M.S., Hamid O., Lawrence D., McDermott D., Puzanov I., Wolchok J.D., Clark J.I., Sznol M., Logan T.F., et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012, 13:459-465.
61. McGowan P.M., Simedrea C., Ribot E.J., Foster P.J., Palmieri D., Steeg P.S., Allan A.L., Chambers A.F. Notch1 inhibition alters the CD44hi/CD24lo population and reduces the formation of brain metastases from breast cancer. Mol. Cancer Res. 2011, 9:834-844.
62. Mendes O., Kim H.T., Lungu G., Stoica G. MMP2 role in breast cancer brain metastasis development and its regulation by TIMP2 and ERK1/2. Clin. Exp. Metastasis 2007, 24:341-351.
63. Mittapalli R.K., Liu X., Adkins C.E., Nounou M.I., Bohn K.A., Terrell T.B., Qhattal H.S., Geldenhuys W.J., Palmieri D., Steeg P.S., et al. Paclitaxel-hyaluronic nanoconjugates prolong overall survival in a preclinical brain metastases of breast cancer model. Mol. Cancer Ther. 2013, 12:2389-2399.
64. Monsky W.L., Mouta Carreira C., Tsuzuki Y., Gohongi T., Fukumura D., Jain R.K. Role of host microenvironment in angiogenesis and microvascular functions in human breast cancer xenografts: mammary fat pad versus cranial tumors. Clin. Cancer Res. 2002, 8:1008-1013.
65. Morikawa A., Peereboom D.M., Smith Q.R., Thorsheim H., Lockman P.R., Simmons A.J., Weil R.J., Tabar V., Steeg P.S., Seidman A.D. Clinical evidence for drug penetration of capecitabine and lapatinib uptake in resected brain metastases from women with metastatic breast cancer. J.Clin. Oncol. 2013, 31(May 20 Suppl):15.
66. Murrell D.H., Foster P.J., Chambers A.F. Brain metastases from breast cancer: lessons from experimental magnetic resonance imaging studies and clinical implications. J.Mol. Med. 2014, 92:5-12.
67. Nakayama A., Takagi S., Yusa T., Yaguchi M., Hayashi A., Tamura T., Kawakita Y., Ishikawa T., Ohta Y. Antitumor activity of TAK-285, an investigational, non-pgp substrate HER2/EGFR kinase inhibitor, in cultured tumor cells, mouse and rat xenograft tumors, and in an HER2-positive brain metastasis model. J.Cancer 2013, 4:557-565.
68. Nanni P., Nicoletti G., Palladini A., Croci S., Murgo A., Ianzano M.L., Grosso V., Stivani V., Antognoli A., Lamolinara A., et al. Multiorgan metastasis of human HER-2+ breast cancer in Rag2-/-;Il2rg-/- mice and treatment with PI3K inhibitor. PLoS ONE 2012, 7:e39626.
69. Neman J., Choy C., Kowolik C.M., Anderson A., Duenas V.J., Waliany S., Chen B.T., Chen M.Y., Jandial R. Co-evolution of breast-to-brain metastasis and neural progenitor cells. Clin. Exp. Metastasis 2013, 30:753-768.
70. Niikura N., Liu J., Hayashi N., Mittendorf E.A., Gong Y., Palla S.L., Tokuda Y., Gonzalez-Angulo A.M., Hortobagyi G.N., Ueno N.T. Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors. J.Clin. Oncol. 2012, 30:593-599.
71. Okuda H., Xing F., Pandey P.R., Sharma S., Watabe M., Pai S.K., Mo Y.Y., Iiizumi-Gairani M., Hirota S., Liu Y., et al. miR-7 suppresses brain metastasis of breast cancer stem-like cells by modulating KLF4. Cancer Res. 2013, 73:1434-1444.
72. Olson E.M., Abdel-Rasoul M., Maly J., Wu C.S., Lin N.U., Shapiro C.L. Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab. Ann. Oncol. 2013, 24:1526-1533.
73. Ousman S.S., Kubes P. Immune surveillance in the central nervous system. Nat. Neurosci. 2012, 15:1096-1101.
74. Palmieri D., Lockman P.R., Thomas F.C., Hua E., Herring J., Hargrave E., Johnson M., Flores N., Qian Y., Vega-Valle E., et al. Vorinostat inhibits brain metastatic colonization in a model of triple-negative breast cancer and induces DNA double-strand breaks. Clin. Cancer Res. 2009, 15:6148-6157.
75. Park E.S., Kim S.J., Kim S.W., Yoon S.L., Leem S.H., Kim S.B., Kim S.M., Park Y.Y., Cheong J.H., Woo H.G., et al. Cross-species hybridization of microarrays for studying tumor transcriptome of brain metastasis. Proc. Natl. Acad. Sci. USA 2011, 108:17456-17461.
76. Pierga J.Y., Bidard F.C., Cropet C., Tresca P., Dalenc F., Romieu G., Campone M., Mahier Aït-Oukhatar C., Le Rhun E., Gonçalves A., et al. Circulating tumor cells and brain metastasis outcome in patients with HER2-positive breast cancer: the LANDSCAPE trial. Ann. Oncol. 2013, 24:2999-3004.
77. Qian Y., Hua E., Bisht K., Woditschka S., Skordos K.W., Liewehr D.J., Steinberg S.M., Brogi E., Akram M.M., Killian J.K., et al. Inhibition of Polo-like kinase 1 prevents the growth of metastatic breast cancer cells in the brain. Clin. Exp. Metastasis 2011, 28:899-908.
78. Robert N.J., Diéras V., Glaspy J., Brufsky A.M., Bondarenko I., Lipatov O.N., Perez E.A., Yardley D.A., Chan S.Y., Zhou X., et al. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J.Clin. Oncol. 2011, 29:1252-1260.
79. Rosner D., Nemoto T., Lane W.W. Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 1986, 58:832-839.
80. Saldana S.M., Lee H.H., Lowery F.J., Khotskaya Y.B., Xia W., Zhang C., Chang S.S., Chou C.K., Steeg P.S., Yu D., Hung M.C. Inhibition of type I insulin-like growth factor receptor signaling attenuates the development of breast cancer brain metastasis. PLoS ONE 2013, 8:e73406.
81. Sevenich L., Bowman R.L., Mason S.D., Quail D.F., Rapaport F., Elie B.T., Brogi E., Brastianos P.K., Hahn W.C., Holsinger L.J., et al. Analysis of tumour- and stroma-supplied proteolytic networks reveals a brain-metastasis-promoting role for cathepsin S. Nat. Cell Biol. 2014, 16:876-888.
82. Sperduto P.W., Kased N., Roberge D., Xu Z., Shanley R., Luo X., Sneed P.K., Chao S.T., Weil R.J., Suh J., et al. Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. J.Clin. Oncol. 2012, 30:419-425.
83. Sperduto P.W., Kased N., Roberge D., Chao S.T., Shanley R., Luo X., Sneed P.K., Suh J., Weil R.J., Jensen A.W., et al. The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer. J.Neurooncol. 2013, 112:467-472.
84. Stemmler H.J., Heinemann V. Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challenge. Oncologist 2008, 13:739-750.
85. Stemmler H.J., Schmitt M., Willems A., Bernhard H., Harbeck N., Heinemann V. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier. Anticancer Drugs 2007, 18:23-28.
86. Tamura K., Kurihara H., Yonemori K., Tsuda H., Suzuki J., Kono Y., Honda N., Kodaira M., Yamamoto H., Yunokawa M., et al. 64Cu-DOTA-trastuzumab PET imaging in patients with HER2-positive breast cancer. J.Nucl. Med. 2013, 54:1869-1875.
87. Taskar K.S., Rudraraju V., Mittapalli R.K., Samala R., Thorsheim H.R., Lockman J., Gril B., Hua E., Palmieri D., Polli J.W., et al. Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm. Res. 2012, 29:770-781.
88. Thomas F.C., Taskar K., Rudraraju V., Goda S., Thorsheim H.R., Gaasch J.A., Mittapalli R.K., Palmieri D., Steeg P.S., Lockman P.R., Smith Q.R. Uptake of ANG1005, a novel paclitaxel derivative, through the blood-brain barrier into brain and experimental brain metastases of breast cancer. Pharm. Res. 2009, 26:2486-2494.
89. Valiente M., Obenauf A.C., Jin X., Chen Q., Zhang X.H., Lee D.J., Chaft J.E., Kris M.G., Huse J.T., Brogi E., Massagué J. Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell 2014, 156:1002-1016.
90. Verma S., Miles D., Gianni L., Krop I.E., Welslau M., Baselga J., Pegram M., Oh D.Y., Diéras V., Guardino E., et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. N.Engl. J. Med. 2012, 367:1783-1791.
91. Winkler F., Kozin S.V., Tong R.T., Chae S.S., Booth M.F., Garkavtsev I., Xu L., Hicklin D.J., Fukumura D., di Tomaso E., et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004, 6:553-563.
92. Xiong Z., Gharagozlou S., Vengco I., Chen W., Ohlfest J.R. Effective CpG immunotherapy of breast carcinoma prevents but fails to eradicate established brain metastasis. Clin. Cancer Res. 2008, 14:5484-5493.
93. Yamamoto D., Iwase S., Tsubota Y., Sueoka N., Yamamoto C., Kitamura K., Odagiri H., Nagumo Y. Bevacizumab in the treatment of five patients with breast cancer and brain metastases: Japan Breast Cancer Research Network-07 trial. Onco Targets Ther. 2012, 5:185-189.
94. Yap T.A., Vidal L., Adam J., Stephens P., Spicer J., Shaw H., Ang J., Temple G., Bell S., Shahidi M., et al. Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J.Clin. Oncol. 2010, 28:3965-3972.
95. Yonemori K., Tsuta K., Ono M., Shimizu C., Hirakawa A., Hasegawa T., Hatanaka Y., Narita Y., Shibui S., Fujiwara Y. Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer. Cancer 2010, 116:302-308.
96. Zhang M., Olsson Y. Reactions of astrocytes and microglial cells around hematogenous metastases of the human brain. Expression of endothelin-like immunoreactivity in reactive astrocytes and activation of microglial cells. J.Neurol. Sci. 1995, 134:26-32.
97. Zhang L., Sullivan P.S., Goodman J.C., Gunaratne P.H., Marchetti D. MicroRNA-1258 suppresses breast cancer brain metastasis by targeting heparanase. Cancer Res. 2011, 71:645-654.
98. Zhang L., Ridgway L.D., Wetzel M.D., Ngo J., Yin W., Kumar D., Goodman J.C., Groves M.D., Marchetti D. The identification and characterization of breast cancer CTCs competent for brain metastasis. Sci. Transl. Med. 2013, 5:180ra148.